Eileen Emison
About Eileen Emison
Eileen Emison is the Director of WW Commercial - Deucravacitinib at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in clinical pharmacogenetics and medical strategy.
Current Role at Bristol Myers Squibb
Eileen Emison is currently the Director, WW Commercial for deucravacitinib at Bristol Myers Squibb. She operates out of Princeton, New Jersey, United States. In this role, she oversees commercial strategies and implementation for deucravacitinib, a therapeutic agent aimed at treating autoimmune diseases.
Previous Roles at Bristol Myers Squibb
Eileen Emison has held several key positions at Bristol Myers Squibb over the years. She served as Director, Professional Marketing for Eliquis from 2018 to 2021. Prior to that, she was the Eliquis Medical Lead for US Medical from 2014 to 2021. She also worked as Director for CV Medical Strategy in 2014 and as Associate Director for the same division from 2010 to 2014. Her earlier roles include Associate Director and Principal Scientist in Clinical Pharmacogenetics, and Sr. Research Investigator I & II in Clinical Pharmacogenetics.
Educational Background
Eileen Emison holds a Doctor of Philosophy (PhD) in Human Genetics and Molecular Biology from The Johns Hopkins University. She also earned a Bachelor of Science (B.S.) in Biology - Anatomy and Physiology from Towson University. Her academic background has provided a solid foundation for her extensive career in medical and commercial strategy.
Experience in Medical Strategy
Eileen Emison has a comprehensive background in medical strategy. She led the medical matrix team in developing strategies and executing deliverables for the launch of two in-line cardiovascular indications. Additionally, she previously led the Clinical Pharmacogenetics team, developing strategic plans and overseeing execution for clinical programs across various stages of development and therapeutic areas.
Expertise in Clinical Development and Commercialization
Eileen Emison possesses broad knowledge of clinical development and commercialization. She has demonstrated success in leading complex teams within several joint-company alliances. Her expertise extends across clinical pharmacogenetics, cardiovascular medical strategy, and professional marketing, making her a versatile leader in the pharmaceutical industry.